410 related articles for article (PubMed ID: 34384473)
1. Kidney cancer biomarkers and targets for therapeutics: survivin (BIRC5), XIAP, MCL-1, HIF1α, HIF2α, NRF2, MDM2, MDM4, p53, KRAS and AKT in renal cell carcinoma.
Li F; Aljahdali IAM; Zhang R; Nastiuk KL; Krolewski JJ; Ling X
J Exp Clin Cancer Res; 2021 Aug; 40(1):254. PubMed ID: 34384473
[TBL] [Abstract][Full Text] [Related]
2. Synergistic roles of p53 and HIF1α in human renal cell carcinoma-cell apoptosis responding to the inhibition of mTOR and MDM2 signaling pathways.
Liu QJ; Shen HL; Lin J; Xu XH; Ji ZG; Han X; Shang DH; Yang PQ
Drug Des Devel Ther; 2016; 10():745-55. PubMed ID: 26937175
[TBL] [Abstract][Full Text] [Related]
3. Tissue-based molecular markers for renal cell carcinoma.
Rink M; Chun FK; Robinson B; Sun M; Karakiewicz PI; Bensalah K; Fisch M; Scherr DS; Lee RK; Margulis V; Shariat SF
Minerva Urol Nefrol; 2011 Dec; 63(4):293-308. PubMed ID: 21996985
[TBL] [Abstract][Full Text] [Related]
4. Opposite prognostic roles of HIF1α and HIF2α expressions in bone metastatic clear cell renal cell cancer.
Szendrői A; Szász AM; Kardos M; Tőkés AM; Idan R; Szűcs M; Kulka J; Nyirády P; Szendrői M; Szállási Z; Győrffy B; Tímár J
Oncotarget; 2016 Jul; 7(27):42086-42098. PubMed ID: 27244898
[TBL] [Abstract][Full Text] [Related]
5. p53 and MDM2 in renal cell carcinoma: biomarkers for disease progression and future therapeutic targets?
Noon AP; Vlatković N; Polański R; Maguire M; Shawki H; Parsons K; Boyd MT
Cancer; 2010 Feb; 116(4):780-90. PubMed ID: 20052733
[TBL] [Abstract][Full Text] [Related]
6. Overexpression of XIAP expression in renal cell carcinoma predicts a worse prognosis.
Mizutani Y; Nakanishi H; Li YN; Matsubara H; Yamamoto K; Sato N; Shiraishi T; Nakamura T; Mikami K; Okihara K; Takaha N; Ukimura O; Kawauchi A; Nonomura N; Bonavida B; Miki T
Int J Oncol; 2007 Apr; 30(4):919-25. PubMed ID: 17332931
[TBL] [Abstract][Full Text] [Related]
7. Hypoxia, Hypoxia-inducible Transcription Factors, and Renal Cancer.
Schödel J; Grampp S; Maher ER; Moch H; Ratcliffe PJ; Russo P; Mole DR
Eur Urol; 2016 Apr; 69(4):646-657. PubMed ID: 26298207
[TBL] [Abstract][Full Text] [Related]
8. A novel small molecule FL118 that selectively inhibits survivin, Mcl-1, XIAP and cIAP2 in a p53-independent manner, shows superior antitumor activity.
Ling X; Cao S; Cheng Q; Keefe JT; Rustum YM; Li F
PLoS One; 2012; 7(9):e45571. PubMed ID: 23029106
[TBL] [Abstract][Full Text] [Related]
9. Rho-associated kinase 1 inhibition is synthetically lethal with von Hippel-Lindau deficiency in clear cell renal cell carcinoma.
Thompson JM; Nguyen QH; Singh M; Pavesic MW; Nesterenko I; Nelson LJ; Liao AC; Razorenova OV
Oncogene; 2017 Feb; 36(8):1080-1089. PubMed ID: 27841867
[TBL] [Abstract][Full Text] [Related]
10. Vascular cell adhesion molecule 1 predicts cancer-free survival in clear cell renal carcinoma patients.
Shioi K; Komiya A; Hattori K; Huang Y; Sano F; Murakami T; Nakaigawa N; Kishida T; Kubota Y; Nagashima Y; Yao M
Clin Cancer Res; 2006 Dec; 12(24):7339-46. PubMed ID: 17189405
[TBL] [Abstract][Full Text] [Related]
11. Kras mutation subtypes distinctly affect colorectal cancer cell sensitivity to FL118, a novel inhibitor of survivin, Mcl-1, XIAP, cIAP2 and MdmX.
Thangaiyan R; Aljahdali IA; Lent-Moore KY; Liao J; Ling X; Li F
Am J Transl Res; 2021; 13(7):7458-7474. PubMed ID: 34377229
[TBL] [Abstract][Full Text] [Related]
12. Anticancer drug FL118 is more than a survivin inhibitor: where is the Achilles' heel of cancer?
Li F
Am J Cancer Res; 2014; 4(3):304-11. PubMed ID: 24959385
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance and expression of PUMA, MCL-1, and p53 in human renal cell carcinoma and para-carcinoma tissues.
Xia HB; Cui HW; Su L; Zhang ZH; Yang XY; Ning SQ; Su XL
Genet Mol Res; 2017 Jul; 16(3):. PubMed ID: 28692117
[TBL] [Abstract][Full Text] [Related]
14. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
[TBL] [Abstract][Full Text] [Related]
15. NRF2/HO-1 axis, BIRC5, and TP53 expression in ESCC and its correlation with clinical pathological characteristics and prognosis.
Gao Y; Wan L; Li M; Wang B; Ma Y
Int J Biol Markers; 2023 Dec; 38(3-4):174-184. PubMed ID: 37312528
[TBL] [Abstract][Full Text] [Related]
16. Mutant Kras as a Biomarker Plays a Favorable Role in FL118-Induced Apoptosis, Reactive Oxygen Species (ROS) Production and Modulation of Survivin, Mcl-1 and XIAP in Human Bladder Cancer.
Santha S; Ling X; Aljahdali IAM; Rasam SS; Wang X; Liao J; Wang J; Fountzilas C; Li Q; Qu J; Li F
Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33217967
[TBL] [Abstract][Full Text] [Related]
17. Genitourinary imaging: part 2, role of imaging in medical management of advanced renal cell carcinoma.
Shinagare AB; Krajewski KM; Jagannathan JP; Ramaiya NH
AJR Am J Roentgenol; 2012 Nov; 199(5):W554-64. PubMed ID: 23096199
[TBL] [Abstract][Full Text] [Related]
18. The genomics of renal cell carcinoma and its role in renal mass biopsy.
Salami SS; George AK; Udager AM
Curr Opin Urol; 2018 Jul; 28(4):383-391. PubMed ID: 29708949
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of key cell cycle regulators in renal cell carcinoma associated with Xp11.2 translocation.
Barroca H; Castedo S; Vieira J; Teixeira M; Müller-Höcker J
Pathol Res Pract; 2009; 205(7):466-72. PubMed ID: 19246164
[TBL] [Abstract][Full Text] [Related]
20. miRNAs as potential game-changers in renal cell carcinoma: Future clinical and medicinal uses.
Elballal MS; Sallam AM; Elesawy AE; Shahin RK; Midan HM; Elrebehy MA; Elazazy O; El-Boghdady RM; Blasy SH; Amer NM; Farid HI; Mohammed DA; Ahmed SA; Mohamed SS; Doghish AS
Pathol Res Pract; 2023 May; 245():154439. PubMed ID: 37028108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
